Overview

Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody

Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label, 2-arm study in which patients are randomized to receive either the formulation that is being used in clinical trials or the formulation that will be used when if the drug becomes commercially available. The purpose of this study is to compare the pharmacokinetics of the two formulations.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Antibodies
Antibodies, Monoclonal
Ipilimumab
Tremelimumab